Open Access

Neurotransmitter alterations in embryonic succinate semialdehyde dehydrogenase (SSADH) deficiency suggest a heightened excitatory state during development

  • Erwin EW Jansen1,
  • Eduard Struys1,
  • Cornelis Jakobs1,
  • Elizabeth Hager2,
  • O Carter Snead3 and
  • K Michael Gibson2, 4, 5Email author
BMC Developmental Biology20088:112

https://doi.org/10.1186/1471-213X-8-112

Received: 17 June 2008

Accepted: 28 November 2008

Published: 28 November 2008

Abstract

Background

SSADH (aldehyde dehydrogenase 5a1 (Aldh5a1); γ-hydroxybutyric (GHB) aciduria) deficiency is a defect of GABA degradation in which the neuromodulators GABA and GHB accumulate. The human phenotype is that of nonprogressive encephalopathy with prominent bilateral discoloration of the globi pallidi and variable seizures, the latter displayed prominently in Aldh5a1-/- mice with lethal convulsions. Metabolic studies in murine neural tissue have revealed elevated GABA [and its derivatives succinate semialdehyde (SSA), homocarnosine (HC), 4,5-dihydroxyhexanoic acid (DHHA) and guanidinobutyrate (GB)] and GHB [and its analogue D-2-hydroxyglutarate (D-2-HG)] at birth. Because of early onset seizures and the neurostructural anomalies observed in patients, we examined metabolite features during Aldh5a1-/- embryo development.

Methods

Embryos were obtained from pregnant dams sacrificed at E (embryo day of life) 10–13, 14–15, 16–17, 18–19 and newborn mice. Intact embryos were extracted and metabolites quantified by isotope dilution mass spectrometry (n = 5–15 subjects, Aldh5a1+/+ and Aldh5a1-/-) for each gestational age group. Data was evaluated using the t test and one-way ANOVA with Tukey post hoc analysis. Significance was set at the 95th centile.

Results

GABA and DHHA were significantly elevated at all gestational ages in Aldh5a1-/- mice, while GB was increased only late in gestation; SSA was not elevated at any time point. GHB and D-2-HG increased in an approximately linear fashion with gestational age. Correlative studies in human amniotic fluid from SSADH-deficient pregnancies (n = 5) also revealed significantly increased GABA.

Conclusion

Our findings indicate early GABAergic alterations in Aldh5a1-/- mice, possibly exacerbated by other metabolites, which likely induce a heightened excitatory state that may predispose neural networks to epilepsy in these animals.

Background

Succinic semialdehyde dehydrogenase (SSADH) deficiency (aldehyde dehydrogenase 5a1 (Aldh5a1); E.C. 1.2.1.24; OMIM 271980, 610045) is a rare neurometabolic defect of the GABA catabolic pathway (Fig. 1). The phenotype is variably that of a static encephalopathy, associated with developmental delays, hypotonia, ataxia, defects or absence of speech, and seizures [1]. Older patients may demonstrate a prominent component of neuropsychiatric morbidity. A cardinal finding from imaging of patients is hyper-intense signals in the globi pallidi bilaterally [2]. Identification of affected probands is facilitated by detection of increased γ-hydroxybutyric acid (GHB) during routine urine organic acid analysis. GHB, a by-product of defective GABA catabolism (Fig. 1), is a compound with its own unique pharmacological profile, and it remains a topic of debate as to whether it is a neurotransmitter as is the case for its parent compound, GABA [3]. Treatment options for patients are limited and primarily palliative, although recent findings in mice suggest that a ketogenic diet may have therapeutic relevance [4, 5].
Figure 1

Schematic of GABA degradation and metabolites accumulating (arrows adjacent to metabolites) in Aldh5a1 deficiency (depicted by cross-hatched box). Abbreviations: SSA, succinate semialdehyde; α-KG, α-ketoglutarate; D-2-HG, D-2-hydroxyglutarate; DHHA, 4,5-dihydroxyhexanoic acid; TCA, tricarboxylic acid.

In an effort to examine the pathophysiology of SSADH deficiency and explore effective preclinical treatment paradigms, Hogema and coworkers [6] developed a murine knockout model. While lethality does not occur in the early newborn period, this animal demonstrates almost uniform lethality in status epilepticus at about 3–4 weeks of life, associated with a marked failure to thrive. Neurophysiological evaluations have revealed a seizure transition process that progresses from absence to generalized tonic-clonic convulsions [7], associated with marked dysregulation of GABAergic neurotransmission in the presence of essentially normal glutamatergic and GHBergic function [710]. Pharmacotherapeutic approaches to offset early lethality have been described above, but also have included the GHB receptor antagonist NCS-382, the GABAB receptor antagonist CGP 35348, and the irreversible GABA transaminase inhibitor vigabatrin (Fig. 1), the latter perhaps the most widely invoked pharmacotherapy in this disorder, despite potential side-effects [11, 12].

Previous studies from our laboratory have shown that significant elevations of GHB and GABA occur in newborn Aldh5a1-/- mice, and these persist until premature death [13]. Elevations of GHB were accompanied by a progressive decrease in glutamine levels with age, which is of interest since glutamine serves as a key shuttle molecule maintaining astrocytic and neuronal concentrations of glutamate and GABA [14] (Fig. 1). GABA, the GHB precursor, was also significantly elevated in the newborn Aldh5a1-/- mice [13]. Based upon these accumulations, and in view of the seizure phenotype of Aldh5a1-/- mice and the imaging abnormalities observed in human patients, we hypothesized that GABA might be significantly elevated in embryonic Aldh5a1-/- mice. The relevance of this question is underscored by the observation that early in rodent embryonic development, and through the first week of postnatal life, GABA exerts excitatory actions that do not transition to inhibitory potentials until chloride concentrations level out by approximately postnatal week 2 [15, 16]. The current report summarizes our metabolic characterization of Aldh5a1 embryos, and provides evidence that a heightened excitatory state may exist in Aldh5a1-/- mice during early development.

Methods

Husbandry and PCR-genotyping of the Aldh5a1 mutant mouse colony has been previously described [17]. Mutant mice were generated by heterozygous matings (Aldh5a1+/- × Aldh5a1+/-); animals were C57Bl/6 congenics. All procedures involving mice were approved by the Institutional Animal Research Care Committee (ARCC), and were performed in accordance with NIH guidelines for laboratory animals.

Timed matings were established for embryo generation. During daily checking, the identification of a vaginal plug in the dams was set at E6.5, and pregnancies were allowed to continue to predetermined timepoints. Dams were rapidly sacrificed and the embryos dissected on a cold-plate (4°C), being careful to avoid maternal decidua. Embryos were either prepared immediately or stored at -80°C until further work-up. Because dissection of embryos was not feasible, all were identically handled without dissection of neural tissue. Additionally, it might have been optimal to isolate enriched neural tissue from these embryos (e.g., brain). However, GABA exerts activities (and is found in measurable quantities) in peripheral tissues, including liver, kidney and pancreas, and thus in these studies we sought to obtain the most complete picture of GABA (and related metabolites) in these embryos [18]. After weighing, a powder of each embryo was prepared by rapid pulverization in dry-ice/acetone. The powders were reconstituted using phosphate-buffered saline (pH 7.4) at a constant ratio of 0.2 g tissue/ml, extracted with a Dounce homogenizer on ice, and finally clarified by centrifugation. The supernatants were stored for metabolite quantification at -80°C; protein content was determined using the Bradford method with BSA as standard. To achieve a statistically significant number in each group, embryos were grouped as follows: E10-13, E14-15, E16-17, E18-19 and P (postnatal)1. For each group (Aldh5a1+/+, Aldh5a1-/-), n = 5–15 separate subjects.

GABA, D- and L-2-hydroxyglutaric acids (D-2-HG/L-2-HG), SSA, DHHA, GHB and guanidinobutyrate (GB) were quantified by isotope dilution methodology employing either gas chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry (LC/MS-MS) [17, 1923]. The same metabolites were quantified in amniotic fluid specimens submitted for prenatal diagnosis in pregnancies at-risk for Aldh5a1 deficiency. In the amniotic fluids characterized, the subsequent propositus was identified as Aldh5a1-deficient either via enzyme or mutation analysis in blood, or both. Amino acids in clarified supernatants were quantified by HPLC analysis with ninhydrin post-column detection, using established methods [13]. Data was evaluated using the GraphPad Prizm program (version 4.0) using the t test and one-way ANOVA with Tukey post hoc analysis. Significance was set at the 95th centile.

Results

Relevant metabolite findings in embryos of both genotypes (Aldh5a1+/+, Aldh5a1-/-) are described in Figs. 2 and 3. GABA was significantly increased at all embryonic ages as a function of genotype (Fig. 2). The concentration by genotype was roughly constant during embryonic development, although a drop in GABA concentrations at birth in both genotypes failed to reach statistical significance (one-way ANOVA with Tukey post-hoc analysis). The concentration of the GABA transamination reaction product, succinic semialdehyde (SSA), was not different by genotype at any gestational timepoint, implying an efficient conversion of SSA to other intermediates (e.g., DHHA, GHB). As noted in Fig. 3, however, there was considerable variation of SSA with genotype, yet none of the differences achieved statistical significance. While it is tempting to speculate that these variations in SSA might represent biological variation, more likely this reflects methodological variation since SSA is a reactive aldehyde that may be partially lost prior to analytical measurement. Nonetheless, the absence of elevated SSA contrasts with the minor increase previously detected in whole brain extracts of Aldh5a1-/- mice [24]. The putative metabolite of GABA (via further oxidative metabolism of SSA; see Fig. 1), DHHA, increased with gestational age for Aldh5a1-/- mice (Fig. 2), and it was significantly increased at all embryonic ages. For DHHA, there was insufficient material available to examine the concentration at E10-13. Guanidinobutyrate (GB), also believed to derive from GABA, showed a significant increase in Aldh5a1-/- mice, but only later in gestation and at birth (Fig. 2).
Figure 2

Concentrations of GABA, DHHA (4,5-dihydroxyhexanoic acid), SSA (succinate semialdehyde) and GB (guanidinobutyrate) in embryo extracts as a function of developmental age. Statistical analysis performed using a two-tailed t test. Abbreviations: gr, gram; E, embryonic (for example, 10–13 is equivalent to E10–E13); P, postnatal. Note that E 10–13 embryo extracts were not available for measurement of DHHA.

Figure 3

Concentrations of GHB (gamma-hydroxybutyric acid) and D-2-HG (D-2-hydroxyglutarate) in embryo extracts as a function of age. A linear representation of means ± SEM by genotype is depicted as well. Abbreviations and statistical analysis as described in Fig. 2. SEM, standard error of the mean.

GHB was significantly increased with genotype at all embryonic ages (Fig. 3). This increase revealed a linear progression with increasing gestational age, as was the case for the GHB analogue, D-2-hydroxyglutaric acid (D-2-HG; Fig. 1). These data provide further evidence that both species are interrelated in their metabolic sequences. For D-2-HG, the significance at E10–13 was reversed, in that Aldh5a1+/+ mice had significantly larger concentrations than did Aldh5a1-/- mice. The reason for this remains unclear. In the same embryo extracts, we also examined total amino acid patterns to see if particular trends were present. There were no consistently significant differences for any amino acid by genotype, with the exception of GABA. Results for glutamate and glutamine, the direct precursors of GABA, are displayed for E15–17, E18–19 and P1 embryos (Fig. 4). In only a single instance (glutamine, E15–17, p < 0.05), there was no significant difference for either amino acid by genotype, although the trend was for lower levels of both in Aldh5a1-/- mice (Fig. 4). These data are consistent with earlier studies in newborn Aldh5a1-/- mice, in which no differences were observed in glutamine and glutamate by genotype at birth [13, 18]. Of note, however, was the considerable decrease in glutamate levels with age. One way ANOVA with Tukey post hoc analysis revealed a significant difference (p < 0.05) for glutamate levels at E15–17 and E18–19 as compared to the same levels at P1 (Fig. 4). This decrease at birth corresponded to the trend toward lower GABA at birth (Fig. 2) for both genotypes.
Figure 4

Concentrations of glutamate and glutamine in embryo extracts as a function of age. Embryos were grouped as E15–17, 18–19 and day of life 1 (P1). Abbreviations: wt, wild-type (Aldh5a1+/+ mice); mu, mutant (Aldh5a1-/- mice). Statistical analysis performed using a two-tailed t test. One-way ANOVA with Tukey post-hoc analysis revealed a significant decline in glutamate level at birth as compared to E15–17 and E18–19, whereas glutamine levels were not significantly decreased.

The finding of elevated embryonic GABA concentrations suggested that amniotic fluid derived from human pregnancies affected with SSADH (Aldh5a1) deficiency might also demonstrate elevated GABA. We have previously shown that an affected pregnancy can be identified by increased GHB levels in amniotic fluid [25]. Accordingly, we examined GABA and other metabolic intermediates in archival amniotic fluid samples for which an SSADH-deficient fetus had been identified. For these fluids from at-risk pregnancies, Aldh5a1-deficiency was documented for the propositus utilizing either enzyme or molecular studies in blood, or both, and a prior affected proband existed in the family. The normal control value for GHB in amniotic fluid was 1.18 ± 0.08 μmol/L (SEM; range 0.42–2.20, n = 31 samples) while the same value for affected amniotic fluids was 5.78 ± 1.25 μmol/L (range 2.10–8.96, n = 5; p < 0.0001). As depicted in Fig. 5, the GABA concentration in these same affected pregnancies was also significantly elevated (1.38 ± 0.05 (SEM), n = 5 for unaffected; 1.88 ± 0.20, n = 5 for affected; p < 0.05). These data imply that GABA is also increased in the SSADH-deficient human fetus, consistent with our results in the murine embryo studies.
Figure 5

GABA concentration in amniotic fluid derived from pregnancies carrying an affected SSADH-deficient human fetus. Data are depicted as box and whiskers, showing the range of values and quartiles. The box extends from the 25th centile to the 75th centile, with a line at the median (50th centile). Whiskers extend above and below the box to show the highest and lowest values. Statistical analysis performed using a two-tailed t test, n = 5 fluid samples for each group. Concentrations of other metabolites (DHHA, D-2-HG and SSA) were not significantly different as a function of pregnancy status.

Discussion and conclusion

A cardinal manifestation of SSADH deficiency is hyperintense signals in the globi pallidi bilaterally. This is not unique to this disorder, however, and may relate to ongoing oxidative damage [26]. Nonetheless, this feature is prominent on the MRI of documented patients. We recently identified a 19 year-old patient with SSADH deficiency who, having experienced recurrent seizures for 6 years, died suddenly and unexpectedly [27]. Detailed post-mortem examination revealed striking discoloration of the globi pallidi bilaterally. Accordingly, we hypothesized that the CNS of SSADH-deficient patients might be predisposed to neuroanatomical lesions linked to prenatal exposure to supraphysiological concentrations of GHB, GABA and other intermediates known to accumulate in SSADH deficiency. Our laboratory has previously shown that alterations of myelin formation occur in Aldh5a1-/- mice [28]. We have hypothesized that the metabolite accumulations detected in Aldh5a1-/- mice, including GHB and GABA, alter signaling components (MAP kinase and neurosteroids) that link to use-dependent down-regulation of GABAergic receptors. Other groups have demonstrated that myelin abnormalities can induce oxidant stress [29]. The current report supports our findings of metabolite perturbations in neonatal Aldh5a1-/- mice, and has laid the groundwork for exploration of additional pathophysiological studies in embryonic mice.

GABA is significantly elevated in very early embryonic development of Aldh5a1-/- mice; as well, GHB is similarly increased, suggesting that the enzyme responsible for conversion of SSA to GHB, SSA reductase (aldo-keto reductase 7a2; AKR7a2), is also active in early embryonic development. The linear increase in GHB (Fig. 2) would suggest that AKR7a2 is also demonstrating a developmental ontogeny, which has not been previously documented. Rumigny and colleagues [30] demonstrated that putative AKR7a2 activity was, however, roughly constant in different rodent brain regions for the first two months of life. A similar process occurs for the GHB derivative, D-2-HG (Fig. 2). D-2-HG is derived from GHB in a reaction catalyzed by d-2-hydroxyglutarate transhydrogenase (HOT), an enzyme known to manifest a developmental ontogeny in the rodent [31, 32]. The corresponding linear increases for GHB and D-2-HG provides further evidence for the existence of HOT in embryonic rodents, and raises the possibility that D-2-HG may have a pathophysiological role in the developing Aldh5a1-/- embryos, since this compound has been shown to induce oxidative damage in rodent tissues [3336]. The accumulation of D-2-HG was specific, since there was no increase in isomeric L-2-hydroxyglutarate with any embryological age (data not shown).

Previous studies from our laboratory demonstrated a small, yet significant, increase in total brain SSA levels for Aldh5a1-/- mice [24]; conversely, we saw no evidence for accumulation of SSA in developing embryos. These data suggest that the requisite enzymes which convert SSA either to GHB or DHHA are functional at the developmental time-points we examined. Our data for DHHA, a species unique to Aldh5a1 deficiency, were also revealing. The synthetic pathway for DHHA formation remains to be conclusively demonstrated, but it has been proposed that DHHA derives from condensation of SSA with a 2-carbon species related to pyruvate metabolism (e.g., acetyl-CoA, pyruvate, etc; see Fig. 1) [37]. If this hypothesis is correct, potential disruptions of intermediary metabolism are occurring very early in the development of the Aldh5a1 embryo. These perturbations, especially focused in mitochondrial metabolism, may underlie a component of the imaging abnormalities observed in patients. Additionally, we have shown that DHHA is a weak ligand for the GHB receptor [38], possibly potentiating the excitatory state induced by early GABA and GHB accumulation. GABA-related guanidinobutyrate (GB) reached significant increases in Aldh5a1-/- mice at ~E18–19 (Fig. 2). GB is purported to derive through the catalytic action of the arginine glycine amidinotransferase (AGAT) reaction, which normally produces the creatine precursor guanidinoacetate from arginine and glycine. Substitution of GABA for glycine would lead to production of GB, as has been previously demonstrated [17, 39]. Braissant and colleagues [40] demonstrated that AGAT is expressed as early as E12.5 in rat hepatic primordial, and rapidly attains an adult expression pattern thereafter, verifying the importance of creatine formation in the developing embryo. Increased GB in Aldh5a1-/- embryos is consistent with the temporal expression demonstrated by Braissant and colleagues, and suggests that accumulated GABA in these embryos may alter the production of creatine, an important mediator of energy production both in muscle and neural tissue.

During central nervous system (CNS) development, the role of forebrain GABA is switched from an excitatory transmitter to an inhibitory transmitter, the result of an inhibition of calcium influx into postsynaptic neurons derived from the release of GABA. The switch is influenced by the neuronal chloride concentration. Prevailing data suggest that GABA remains excitatory until approximately the first postnatal week in rodents, and that chloride concentrations level out after approximately postnatal week 2. When the neuronal chloride concentration is at a high level, GABA acts as an excitatory neurotransmitter. When neuronal chloride concentration decreases to some degree, GABA acts as an inhibitory neurotransmitter. The neuronal chloride concentration is increased by the Na+-K+-Cl--cotransporter 1 (NKCC1), and decreased by K+-Cl--cotransporter 2 (KCC2) [16, 41, 42]. As well, GABA is thought to have significant effects on cell migration, differentiation, and synaptogenesis, yet fetal brains of mice lacking both GAD65 and GAD67 have 0.02% of normal GABA content and die at birth, but they have no obvious structural brain abnormalities [15]. Thus, the question posed by our data is whether a marked increase in fetal brain GABA affects cell migration, differentiation, and synaptogenesis or has an effect on the propensity for seizures? Elevation of GHB may play a role on GABABR presynaptically, since the presynaptic GABABR is functional at or around birth, but the postsynaptic GABABR is not functional until about P14. Additionally, the combination of elevated GABA plus GHB would be predicted to have a greater summed effect on GABABR since GHB has no affinity for the GABAAR. Another key question is whether elevated GABA in the embryo would alter expression of the cotransporters described above?

Several experiments are underway to address the preceding questions. We are performing pilot studies to evaluate GABA and glutamatergic receptor expression in selected Aldh5a1-/- and Aldh5a1+/+ embryos, in order to test the hypothesis that there is use-dependent down-regulation during development. As well, Western blot studies and real time PCR evaluation of the neuronal ion cotransporters have been planned in conjunction with the preceding evaluations. Studies of axonal and neuronal number and localization have been planned to ascertain if elevations of GHB and GABA have an adverse effect of these parameters during embryo development. Nonetheless, MRI analysis of human Aldh5a1-deficient brain does not provide evidence for structural abnormalities, beyond the characteristic globi pallidi abnormalities observed. Limited neuroimaging in Aldh5a1-/- mice has provided evidence of cerebellar atrophy and some subtle differences in neuronal counts, but more extensive studies are needed [43]. Finally, an emergent approach in our laboratory is to examine methods to deplete elevated GABA and GHB levels in developing embryos. Accordingly, one series of studies in progress is testing the hypothesis that administration of L-histidine to pregnant Aldh5a1+/- dams may drive the formation of homocarnosine from GABA (see Fig. 1) in brain. Whether this has an adverse or positive effect on phenotypic outcome in Aldh5a1-/- mice remains to be determined.

Declarations

Acknowledgements

The authors are indebted to Dr. Qin Sun for assistance with amino acid evaluations, and to Tonia Tse and Patrick Wilson for technical assistance. Supported by NIH NS 40270-07 (KMG and OCS).

Presented in abstract form-Annual Meeting, Society for the Study of Inborn Errors of Metabolism, Sept. 2-5, 2008, Lisbon, Portugal.

Authors’ Affiliations

(1)
Metabolic Unit, Department of Clinical Chemistry, VU Medical Center
(2)
Division of Medical Genetics, Department of Pediatrics, Children's Hospital & the University of Pittsburgh School of Medicine
(3)
Division of Pediatric Neurology, Brain and Behavior Institute, Hospital for Sick Children & the University of Toronto
(4)
Department of Pathology, Biochemical Genetics Laboratory, University of Pittsburgh Medical Center & the University of Pittsburgh School of Medicine
(5)
Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh Medical Center & the University of Pittsburgh School of Medicine

References

  1. Pearl PL, Taylor JL, Trzcinski S, Sokohl A: The pediatric neurotransmitter disorders. J Child Neurol. 2007, 22: 606-616. 10.1177/0883073807302619.View ArticlePubMedGoogle Scholar
  2. Knerr I, Pearl PL, Bottiglieri T, Snead OC, Jakobs C, Gibson KM: Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology. J Inherit Metab Dis. 2007, 30: 279-294. 10.1007/s10545-007-0574-2.View ArticlePubMedGoogle Scholar
  3. Snead OC, Gibson KM: Gamma-hydroxybutyric acid. N Engl J Med. 2005, 352: 2721-2732. 10.1056/NEJMra044047.View ArticlePubMedGoogle Scholar
  4. Nylen K, Velazquez JL, Likhodii SS, Cortez MA, Shen L, Leshchenko Y, Adeli K, Gibson KM, Burnham WM, Snead OC: A ketogenic diet rescues the murine succinic semialdehyde dehydrogenase deficient phenotype. Exp Neurol. 2008, 210: 449-457. 10.1016/j.expneurol.2007.11.015.View ArticlePubMed CentralPubMedGoogle Scholar
  5. Gropman A: Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency. Ann Neurol. 2003, 54 (Suppl 6): 66-72. 10.1002/ana.10626.View ArticleGoogle Scholar
  6. Hogema BM, Gupta M, Senephansiri H, Burlingame TG, Taylor M, Jakobs C, Schutgens RB, Froestl W, Snead OC, Diaz-Arrastia R, Bottiglieri T, Grompe M, Gibson KM: Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. Nat Genet. 2001, 29: 212-216. 10.1038/ng727.View ArticlePubMedGoogle Scholar
  7. Cortez MA, Wu Y, Gibson KM, Snead OC: Absence seizures in succinic semialdehyde dehydrogenase deficient mice: a model of juvenile absence epilepsy. Pharmacol Biochem Behav. 2004, 79: 547-553. 10.1016/j.pbb.2004.09.008.View ArticlePubMedGoogle Scholar
  8. Wu Y, Buzzi A, Frantseva M, Velazquez JP, Cortez M, Liu C, Shen L, Gibson KM, Snead OC: Status epilepticus in mice deficient for succinate semialdehyde dehydrogenase: GABAA receptor-mediated mechanisms. Ann Neurol. 2006, 59: 42-52. 10.1002/ana.20686.View ArticlePubMedGoogle Scholar
  9. Buzzi A, Wu Y, Frantseva MV, Perez Velazquez JL, Cortez MA, Liu CC, Shen LQ, Gibson KM, Snead OC: Succinic semialdehyde dehydrogenase deficiency: GABAB receptor-mediated function. Brain Res. 2006, 1090: 15-22. 10.1016/j.brainres.2006.02.131.View ArticlePubMedGoogle Scholar
  10. Mehta AK, Gould GG, Gupta M, Carter LP, Gibson KM, Ticku MK: Succinate semialdehyde dehydrogenase deficiency does not down-regulate gamma-hydroxybutyric acid binding sites in the mouse brain. Mol Genet Metab. 2006, 88: 86-89. 10.1016/j.ymgme.2005.11.012.View ArticlePubMedGoogle Scholar
  11. Gupta M, Greven R, Jansen EE, Jakobs C, Hogema BM, Froestl W, Snead OC, Bartels H, Grompe M, Gibson KM: Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). J Pharmacol Exp Ther. 2002, 302: 180-187. 10.1124/jpet.302.1.180.View ArticlePubMedGoogle Scholar
  12. Santaella RM, Fraunfelder FW: Ocular adverse effects associated with systemic medications: recognition and management. Drugs. 2007, 67: 75-93. 10.2165/00003495-200767010-00006.View ArticlePubMedGoogle Scholar
  13. Gupta M, Polinsky M, Senephansiri H, Snead OC, Jansen EE, Jakobs C, Gibson KM: Seizure evolution and amino acid imbalances in murine succinate semialdehyde dehydrogenase (SSADH) deficiency. Neurobiol Dis. 2004, 16: 556-562. 10.1016/j.nbd.2004.04.008.View ArticlePubMedGoogle Scholar
  14. Chowdhury GM, Gupta M, Gibson KM, Patel AB, Behar KL: Altered cerebral glucose and acetate metabolism in succinic semialdehyde dehydrogenase-deficient mice: evidence for glial dysfunction and reduced glutamate/glutamine cycling. J Neurochem. 2007, 103: 2077-2091. 10.1111/j.1471-4159.2007.04887.x.View ArticlePubMedGoogle Scholar
  15. Owens DF, Kriegstein AR: Is there more to GABA than synaptic inhibition?. Nat Rev Neurosci. 2002, 3: 715-27. 10.1038/nrn919.View ArticlePubMedGoogle Scholar
  16. Ben-Ari Y, Gaiarsa JL, Tyzio R, Khazipov R: GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol Rev. 2007, 87: 1215-84. 10.1152/physrev.00017.2006.View ArticlePubMedGoogle Scholar
  17. Jansen EE, Verhoeven NM, Jakobs C, Schulze A, Senephansiri H, Gupta M, Snead OC, Gibson KM: Increased guanidino species in murine and human succinate semialdehyde dehydrogenase (SSADH) deficiency. Biochim Biophys Acta. 2006, 1762: 494-498.View ArticlePubMedGoogle Scholar
  18. Gibson KM, Schor DS, Gupta M, Guerand WS, Senephansiri H, Burlingame TG, Bartels H, Hogema BM, Bottiglieri T, Froestl W, Snead OC, Grompe M, Jakobs C: Focal neurometabolic alterations in mice deficient for succinate semialdehyde dehydrogenase. J Neurochem. 2002, 81: 71-79. 10.1046/j.1471-4159.2002.00784.x.View ArticlePubMedGoogle Scholar
  19. Gibson KM, ten Brink HJ, Schor DS, Kok RM, Bootsma AH, Hoffmann GF, Jakobs C: Stable-isotope dilution analysis of D- and L-2-hydroxyglutaric acid: application to the detection and prenatal diagnosis of D- and L-2-hydroxyglutaric acidemias. Pediatr Res. 1993, 34: 277-280. 10.1203/00006450-199309000-00007.View ArticlePubMedGoogle Scholar
  20. Gibson KM, Aramaki S, Sweetman L, Nyhan WL, DeVivo DC, Hodson AK, Jakobs C: Stable isotope dilution analysis of 4-hydroxybutyric acid: an accurate method for quantification in physiological fluids and the prenatal diagnosis of 4-hydroxybutyric aciduria. Biomed Environ Mass Spectrom. 1990, 19: 89-93. 10.1002/bms.1200190207.View ArticlePubMedGoogle Scholar
  21. Struys EA, Jansen EE, Gibson KM, Jakobs C: Determination of the GABA analogue succinic semialdehyde in urine and cerebrospinal fluid by dinitrophenylhydrazine derivatization and liquid chromatography-tandem mass spectrometry: application to SSADH deficiency. J Inherit Metab Dis. 2005, 28: 913-920. 10.1007/s10545-005-0111-0.View ArticlePubMedGoogle Scholar
  22. Struys EA, Verhoeven NM, Jansen EE, Ten Brink HJ, Gupta M, Burlingame TG, Quang LS, Maher T, Rinaldo P, Snead OC, Goodwin AK, Weerts EM, Brown PR, Murphy TC, Picklo MJ, Jakobs C, Gibson KM: Metabolism of gamma-hydroxybutyrate to d-2-hydroxyglutarate in mammals: further evidence for d-2-hydroxyglutarate transhydrogenase. Metabolism. 2006, 55: 353-358. 10.1016/j.metabol.2005.09.009.View ArticlePubMedGoogle Scholar
  23. Kok RM, Howells DW, Heuvel van den CC, Guerand WS, Thompson GN, Jakobs C: Stable isotope dilution analysis of GABA in CSF using simple solvent extraction and electron-capture negative-ion mass fragmentography. J Inherit Metab Dis. 1993, 16: 508-512. 10.1007/BF00711667.View ArticlePubMedGoogle Scholar
  24. Gibson KM, Gupta M, Senephansiri H, Jansen EEW, Montine TJ, Hyland K, Switzer RC, Snead OC, Jakobs C: Oxidant stress and neurodegeneration in murine succinic semialdehyde dehydrogenase (SSADH) deficiency. Diseases of Neurotransmission-from bench to bed. Edited by: Hoffmann GF. 2006, SPS Verlagsgessellschaft mbH, Heilbronn, Germany, Symposia Proceedings, 199-212.Google Scholar
  25. Jakobs C, Ogier H, Rabier D, Gibson KM: Prenatal detection of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria). Prenat Diagn. 1993, 13: 150-10.1002/pd.1970130213.View ArticlePubMedGoogle Scholar
  26. Michel SJ, Given CA, Robertson WC: Imaging of the brain, including diffusion-weighted imaging in methylmalonic acidemia. Pediatr Radiol. 2004, 34: 580-582. 10.1007/s00247-004-1155-2.View ArticlePubMedGoogle Scholar
  27. Knerr I, Gibson KM, Murdoch G, Salomons GS, Pope L, Jakobs C, Catanese GA, Pearl PL: Neuropathology of succinic semialdehyde dehydrogenase (SSADH) deficiency (γ-hydroxybutyric aciduria). J Inherit Metab Dis. 2008, 31 (Suppl 1): 24-Google Scholar
  28. Donarum EA, Stephan DA, Larkin K, Murphy EJ, Gupta M, Senephansiri H, Switzer RC, Pearl PL, Snead OC, Jakobs C, Gibson KM: Expression profiling reveals multiple myelin alterations in murine succinate semialdehyde dehydrogenase deficiency. J Inherit Metab Dis. 2006, 29: 143-56. 10.1007/s10545-006-0247-6.View ArticlePubMedGoogle Scholar
  29. Andrews H, White K, Thomson C, Edgar J, Bates D, Griffiths I, Turnbull D, Nichols P: Increased axonal mitochondrial activity as an adaptation to myelin deficiency in the Shiverer mouse. J Neurosci Res. 2006, 83: 1533-9. 10.1002/jnr.20842.View ArticlePubMedGoogle Scholar
  30. Rumigny JF, Cash C, Mandel P, Maitre M: Ontogeny and distribution of specific succinic semialdehyde reductase apoenzyme in the rat brain. Neurochem Res. 1982, 7: 555-561. 10.1007/BF00965122.View ArticlePubMedGoogle Scholar
  31. Kaufman EE, Nelson T, Fales HM, Levin DM: Isolation and characterization of a hydroxyacid-oxoacid transhydrogenase from rat kidney mitochondria. J Biol Chem. 1988, 263: 16872-16879.PubMedGoogle Scholar
  32. Nelson T, Kaufman EE: Developmental time courses in the brain and kidney of two enzymes that oxidize gamma-hydroxybutyrate. Dev Neurosci. 1994, 16: 352-358. 10.1159/000112129.View ArticlePubMedGoogle Scholar
  33. Kölker S, Pawlak V, Ahlemeyer B, Okun JG, Hörster F, Mayatepek E, Krieglstein J, Hoffmann GF, Köhr G: NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria. Eur J Neurosci. 2002, 16: 21-28. 10.1046/j.1460-9568.2002.02055.x.View ArticlePubMedGoogle Scholar
  34. Latini A, da Silva CG, Ferreira GC, Schuck PF, Scussiato K, Sarkis JJ, Dutra Filho CS, Wyse AT, Wannmacher CM, Wajner M: Mitochondrial energy metabolism is markedly impaired by D-2-hydroxyglutaric acid in rat tissues. Mol Genet Metab. 2005, 86: 188-199. 10.1016/j.ymgme.2005.05.002.View ArticlePubMedGoogle Scholar
  35. da Silva CG, Bueno AR, Schuck PF, Leipnitz G, Ribeiro CA, Wannmacher CM, Wyse AT, Wajner M: D-2-hydroxyglutaric acid inhibits creatine kinase activity from cardiac and skeletal muscle of young rats. Eur J Clin Invest. 2003, 33: 840-847. 10.1046/j.1365-2362.2003.01237.x.View ArticlePubMedGoogle Scholar
  36. Junqueira D, Brusque AM, Porciúncula LO, Rotta LN, Frizzo ME, Wyse AT, Wannmacher CM, Souza DO, Wajner M: In vitro effects of D-2-hydroxyglutaric acid on glutamate binding, uptake and release in cerebral cortex of rats. J Neurol Sci. 2004, 217: 189-194. 10.1016/j.jns.2003.10.005.View ArticlePubMedGoogle Scholar
  37. Brown GK, Cromby CH, Manning NJ, Pollitt RJ: Urinary organic acids in succinic semialdehyde dehydrogenase deficiency: evidence of alpha-oxidation of 4-hydroxybutyric acid, interaction of succinic semialdehyde with pyruvate dehydrogenase and possible secondary inhibition of mitochondrial beta-oxidation. J Inherit Metab Dis. 1987, 10: 367-375. 10.1007/BF01799979.View ArticlePubMedGoogle Scholar
  38. Struys EA: D-2-Hydroxyglutaric aciduria: unravelling the biochemical pathway and the genetic defect. J Inherit Metab Dis. 2006, 29: 21-29. 10.1007/s10545-006-0317-9.View ArticlePubMedGoogle Scholar
  39. Schulze A, Mayatepek E, Frank S, Marescau B, De Deyn PP, Bachert P: Disturbed metabolism of guanidine compounds characterized by elevated excretion of β-guanidinopropionic acid and γ-guanidinobutyric acid – An effect of vigabatrin treatment?. J Inherit Metab Dis. 1998, 21: 268-271. 10.1023/A:1005376307471.View ArticlePubMedGoogle Scholar
  40. Braissant O, Henry H, Villard AM, Speer O, Wallimann T, Bachmann C: Creatine synthesis and transport during rat embryogenesis: spatiotemporal expression of AGAT, GAMT and CT1. BMC Dev Biol. 2005, 5: 9-10.1186/1471-213X-5-9.View ArticlePubMed CentralPubMedGoogle Scholar
  41. Rheims S, Minlebaev M, Ivanov A, Represa A, Khazipov R, Holmes GL, Ben-Ari Y, Zilberter Y: Excitatory GABA in Rodent Developing Neocortex in vitro. J Neurophysiol. 2008, 100: 609-19. 10.1152/jn.90402.2008.View ArticlePubMedGoogle Scholar
  42. Wang DD, Kriegstein AR: GABA regulates excitatory synapse formation in the neocortex via NMDA receptor activation. J Neurosci. 2008, 28: 5547-58. 10.1523/JNEUROSCI.5599-07.2008.View ArticlePubMed CentralPubMedGoogle Scholar
  43. Acosta M, Munasinghe J, Theodore WH, Gibson KM, Gupta M, Pearl P, Rogawski MA: Brain MRI and histology in a murine model of inherited succinic semialdehyde dehydrogenase (SSADH) deficiency. J Inherit Metab Dis. 2005, 28 (Suppl 1): 234-Google Scholar

Copyright

© Jansen et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.